GSDMD-NETs in patients with sepsis-induced coagulopathy and their interaction with glycocalyx damage

Abstract

Introduction:

Neutrophil extracellular traps (NETs) play a critical role in inflammation and coagulation imbalance. Recent studies have demonstrated that activation of gasdermin D (GSDMD) protein and its pore-forming activity are essential drivers of NET generation. This study investigated the association between GSDMD-NETs axis activation and sepsis-induced coagulopathy (SIC), as well as the potential association with glycocalyx damage.

Materials and Methods:

A prospective cohort of 70 sepsis patients (35 with SIC, 35 non-SIC) admitted to a respiratory intensive care unit was analyzed. This study was registered at the Chinese Clinical Trial Registry (ChiCTR) with the registration number ChiCTR2500100284. The trial can be accessed at https://www.chictr.org.cn/bin/project/edit?pid=266738. Plasma levels of GSDMD-NETs biomarkers (N-GSDMD, MPO-DNA) and glycocalyx injury markers (syndecan-1, MMP-9) were measured via ELISA. Clinical outcomes, thrombotic/hemorrhagic events, and biomarker correlations were evaluated using logistic regression, ROC analysis, and Pearson’s correlation.

Results:

Compared to non-SIC patients, the SIC group exhibited higher rates of viral infections (31.4% vs. 11.4%, P = 0.043), hemorrhagic events (48.6% vs. 17.1%, P = 0.005), and in-hospital mortality (40.0% vs. 17.1%, P = 0.034). SIC patients demonstrated significantly elevated GSDMD-NETs axis biomarkers (N-GSDMD: 481.302 vs. 539.033, P < 0.001; MPO-DNA: 376.708 vs. 461.847, P < 0.001) and glycocalyx damage markers (syndecan-1: 367.754 vs. 431.186, P=< 0.001; MMP-9: 121.550 vs. 133.931, p = 0.009). GSDMD-NETs biomarkers independently predicted SIC risk (MPO-DNA: OR 1.015, 95% CI 1.005–1.025; N-GSDMD: OR 1.018, 95% CI 1.005–1.031). ROC analysis revealed predictive efficacy for SIC (N-GSDMD: AUC 0.786; MPO-DNA: AUC 0.772), with enhanced performance for their combination (AUC: 0.859). Similarly, the combined biomarkers predicted mechanical ventilation (AUC: 0.755) and mortality (AUC: 0.767). MPO-DNA correlated with syndecan-1 (r = 0.856, p < 0.001) and MMP-9 (r = 0.595, p < 0.001), while N-GSDMD correlated with syndecan-1 (r = 0.343, p = 0.004) and MMP-9 (r = 0.509, p = 0.042).

Conclusion:

The activation of the GSDMD-NETs axis is strongly associated with the development of SIC, glycocalyx injury, and adverse clinical outcomes in sepsis, potentially contributing to these pathological processes. Plasma N-GSDMD and MPO-DNA serve as predictive biomarkers for SIC severity and mortality, highlighting their potential role in targeted therapeutic strategies.

1 Introduction

Sepsis, a life-threatening dysregulated host response to infection, is characterized by a complex interplay of inflammatory activation and coagulopathic derangements (1). Although physiologic coagulation activation serves as a critical defense mechanism against microbial invasion, its pathological amplification initiates a self-perpetuating cascade of immuno-thrombosis, clotting factor depletion, and subsequent progression to sepsis-induced coagulopathy (SIC). Left unabated, this process culminates in disseminated intravascular coagulation (DIC), multi-organ dysfunction syndrome, and ultimately mortality (2). Despite its clinical significance, the molecular drivers of SIC remain incompletely characterized, limiting targeted therapeutic development.

Emerging mechanistic insights have identified neutrophil extracellular traps (NETs) - chromatin-based antimicrobial structures released through neutrophil death - as central orchestrators of immuno-thrombotic pathology in SIC progression (3, 4). Seminal studies established that GSDMD pore-forming activity, activated through caspase-mediated proteolytic cleavage, serves as an essential prerequisite for NET generation (5, 6). These foundational findings position the GSDMD-NETs axis as a pivotal molecular switch that may be associated with the pathogenesis of SIC. Within the GSDMD - NETs signaling axis, N-terminal gasdermin D (N - GSDMD) acts as the central initiator protein. MPO - DNA complexes serve as a characteristic marker of NETs (7). The activation of the GSDMD - NETs axis can be assessed by measuring the plasma levels of N - GSDMD and MPO - DNA.

Concurrently, the vascular endothelium maintains hemostatic balance through multifaceted regulatory networks, with the endothelial glycocalyx serving as a gatekeeper of thromboresistance, barrier integrity, and inflammatory signaling (8, 9). This dynamic proteoglycan matrix demonstrates marked vulnerability to septic insults, where its degradation not only exacerbates endothelial dysfunction but also establishes a pro-thrombotic milieu permissive for SIC development (10, 11). Specifically, Syndecan - 1, a key component of the glycocalyx, sheds into the bloodstream and results in an elevated plasma concentration, which indicates the damage of the glycocalyx (12). Matrix metalloproteinase - 9 (MMP - 9) is an enzyme involved in glycocalyx degradation, and its increased level is correlated with the extent of glycocalyx injury (13–15).

Building on these insights, this study investigates two interrelated dimensions: (1) the clinical association between GSDMD-mediated NET formation biomarkers and SIC severity, and (2) the possible correlation between GSDMD - NETs axis activation and glycocalyx degradation in septic coagulopathy.

2 Materials and methods

2.1 Patients and study design

This prospective study, approved by the Ethics Committee of Yantai Yuhuangding Hospital (Approval No. 2023-238) and registered on the Chinese Clinical Trial Registry (ChiCTR2500100284), was conducted from June 2023 to June 2024. The protocol complied with the principles of the Declaration of Helsinki principles and the Ethical Review Measures for Biomedical Research Involving Humans. Written informed consent was obtained from all participants or their legal surrogates prior to enrollment. Consecutively screened adult patients (≥18 years) meeting Sepsis-3 criteria (16) were enrolled within 24 hours of admission to the Respiratory Intensive Care Unit (RICU). SIC classification was determined using the 2017 ISTH criteria (17), requiring concurrent assessment of platelet count, prothrombin time, and SOFA score during the initial 24-hour observation window. Exclusion criteria included: 1) death or discharge against medical advice within 24 hours post-enrollment; 2) pre-admission diagnosis of overt DIC; 3) age <18 years; 4) non-consenting status. All patients received protocolized care according to the 2021 Surviving Sepsis Campaign Guidelines (18), including antimicrobial stewardship, hemodynamic monitoring, and organ support therapies.

During the study period, a total of 98 patients were admitted with a diagnosis of sepsis. Among them, 1 patient was excluded for being under 18 years old, 11 patients died within 24 hours after admission, and 7 patients were excluded for having overt disseminated intravascular coagulation (DIC) at the time of admission. Additionally, 9 patients refused to sign the informed consent form. Therefore, a total of 70 patients were included in our study, of whom 35 met the criteria for SIC (Figure 1).

Figure 1

2.2 Collection of clinical data and outcomes

Within 24 hours of RICU admission, comprehensive clinical characterization was performed including structured history-taking, systematic laboratory profiling, and quantification of plasma biomarkers reflecting GSDMD-NETs axis activation and glycocalyx integrity. Standardized data collection encompassed demographics (age/sex), comorbidities, inflammatory markers (procalcitonin, CRP, neutrophil/lymphocyte counts), nutritional status (albumin), and coagulation parameters (D-dimer). Thrombotic events were defined as radiologically confirmed deep-vein thrombosis, pulmonary embolism, or acute arterial thrombosis (coronary/cerebral/peripheral). Hemorrhagic complications included endoscopically/proven gastrointestinal bleeding, imaging-confirmed intracranial hemorrhage, or macroscopic hematuria. Mechanical ventilation requirement and in-hospital mortality were tracked as clinical endpoints.

2.3 Sample collection and ELISA assay operations

Within 24 hours after admission, venous blood samples were collected into ethylenediaminetetraacetic acid (EDTA) tubes and processed within 30 minutes (3000 g for 15 minutes at 4°C). The samples were then aliquoted and stored at -80°C until batch analysis.

According to the manufacturer’s instructions, the levels of serum MPO - DNA, N - GSDMD, MMP - 9, and Syndecan - 1 were measured using commercial ELISA kits (Jiangsu Meimian Industrial Co., Ltd). The specific kits used were the Human MPO - DNA ELISA kit (Catalog No.: MM - 2467H1), Human N - GSDMD ELISA kit (Catalog No.: MM - 51628H1), Human MMP - 9 ELISA kit (Catalog No.: MM - 0149H1), and Human Syndecan - 1 ELISA kit (Catalog No.: MM - 1818H1). The operations were carried out strictly following the manufacturer’s protocols.

The provided microplates were pre - coated with corresponding specific antibodies. Standards and samples were added to the appropriate wells of the microplate, with three replicate wells set for each standard or sample. Subsequently, the corresponding biotin - conjugated antibodies were added. A color change occurred because of the reaction between the biotin - conjugated antibodies and the enzyme - conjugated avidin. The enzyme - substrate reaction was terminated by adding sulfuric acid solution, and then the color change was measured at a wavelength of 450 nm using a spectrophotometer. A standard curve was plotted by measuring the absorbance and concentration of the standards. The concentration of the samples was determined by comparing the absorbance values of the samples with the standard curve.

2.4 Statistical analysis

Continuous variables adhering to a normal distribution were evaluated with the independent samples t-test, with outcomes reported as mean ± standard deviation. For datasets violating normality assumptions, nonparametric comparisons were performed using the Wilcoxon rank-sum test (Mann-Whitney U equivalent), and results are summarized using median values with interquartile ranges. Dichotomous and categorical parameters underwent comparative analysis through Pearson’s chi-square test or Fisher’s exact probability test where appropriate, with frequency distributions expressed as percentages. A multivariable logistic regression model was constructed to assess potential predictors associated with SIC risk stratification. The predictive performance of plasma GSDMD-NETs biomarker levels for SIC, in-hospital mortality, and mechanical ventilation requirement was evaluated through receiver operating characteristic (ROC) curve analysis. The association between plasma levels of GSDMD-NETs biomarkers (e.g., N-GSDMD, MPO-DNA) and glycocalyx injury markers (e.g., syndecan-1, MMP-9) was analyzed using Pearson’s correlation coefficient. Data analyses were conducted with IBM SPSS Statistics (Version 13.0; SPSS Inc., Chicago, IL, USA) for general statistical procedures and MedCalc (Version 14.8; MedCalc Software Ltd., Ostend, Belgium) for receiver operating characteristic (ROC) curve computations. Statistical significance was defined as a two-sided P<0.05.

3 Result

3.1 Baseline clinical characteristics of the study cohort

A total of 70 sepsis patients were included, 35 with SIC and 35 without SIC. Table 1 presents the baseline characteristics of sepsis patients after ICU admission across different groups. No significant differences were identified between the groups in age or sex distribution. The prevalence of comorbidities, including chronic pulmonary, cardiovascular, cerebrovascular, renal, hepatic diseases, diabetes, and active malignancy, also showed no significant differences between the groups. In terms of pathogens, the distribution was similar except for a higher proportion of viral infections in the SIC group (p = 0.043). Laboratory examinations revealed that the neutrophil-to-lymphocyte ratio (NLR) was significantly higher in the SIC group compared to the non-SIC group (p = 0.040). While levels of procalcitonin (PCT) and C-reactive protein (CRP) were higher in the SIC group, these differences did not reach statistical significance. Similarly, D-dimer levels were elevated in the SIC group but also did not reach statistical significance.

Table 2 presents the GSDMD-NETs axis markers and clinical outcomes in sepsis patients across different groups. The levels of MPO-DNA [376.708 (325.886–445.340) vs. 461.847 (416.237–487.910), p < 0.001] and N-GSDMD [481.302 (459.549–528.518) vs. 539.033 (507.330–602.978), p < 0.001] were significantly higher in the SIC group compared to the non-SIC group, as shown in Figure 2. In terms of clinical outcomes, the SIC group had higher in-hospital mortality (40.0% vs. 17.1%, p = 0.034) and mechanical ventilation rates (58.1% vs. 28.6%, p = 0.029). Thrombotic events showed no significant difference between the groups (45.7% vs. 51.4%, p = 0.632), while hemorrhagic events were significantly higher in the SIC group (48.6% vs. 17.1%, p = 0.005).

Figure 2

3.2 Independent risk factors for sepsis-induced coagulopathy

To identify variables associated with SIC in sepsis patients, a univariate logistic regression analysis was performed. The analysis revealed that Pathogen (Virus), Neutrophil-to-Lymphocyte Ratio, MPO-DNA, and N-GSDMD were associated with SIC. Therefore, these variables were taken into multivariate logistic regression for adjustment. The OR for SIC of MPO-DNA was 1.015 (95% CI, 1.005–1.025, p = 0.003), and N-GSDMD was 1.018 (95% CI, 1.005–1.031, p = 0.006) after adjustment for risk factors (Tables 3, 4).

An ROC curve for SIC occurrence was drawn (Figure 3A). As shown in Table 5, the area under the curve for N-GSDMD was 0.786 (95% CI, 0.679–0.893) with a sensitivity of 0.886 and a specificity of 0.6. The area under the curve for MPO-DNA was 0.772 (95% CI, 0.663–0.881) with a sensitivity of 0.943 and a specificity of 0.514. The combination of N-GSDMD and MPO-DNA showed a statistically significant improvement in predictive efficacy compared to N-GSDMD alone (p = 0.0480) and MPO-DNA alone (p = 0.0475). The area under the curve for the combination was 0.859 (95% CI, 0.773–0.944), indicating a more robust predictive value for SIC.

Figure 3

An ROC curve for SIC occurrence was drawn (Figure 3A). As shown in Table 5, the area under the curve for N-GSDMD was 0.786 (95% CI, 0.679–0.893) with a sensitivity of 0.886 and a specificity of 0.6. The area under the curve for MPO-DNA was 0.772 (95% CI, 0.663–0.881) with a sensitivity of 0.943 and a specificity of 0.514. The combination of N-GSDMD and MPO-DNA showed a statistically significant improvement in predictive efficacy compared to N-GSDMD alone (p = 0.0480) and MPO-DNA alone (p = 0.0475). The area under the curve for the combination was 0.859 (95% CI, 0.773–0.944), indicating a more robust predictive value for SIC.

3.3 Predictive capabilities of GSDMD-NETs axis markers for sepsis patients outcomes

Using ROC curves, the predictive capabilities of N-GSDMD and MPO-DNA for in-hospital mortality and mechanical ventilation were examined (Figures 3B, C). As Table 5 shown, for in-hospital mortality, the AUC for N-GSDMD was 0.683 (95% CI, 0.549–0.817) with a sensitivity of 0.700 and a specificity of 0.740. The AUC for MPO-DNA was 0.767 (95% CI, 0.648–0.886) with a sensitivity of 0.800 and a specificity of 0.640. In contrast to the prediction of SIC, the combination of N-GSDMD and MPO-DNA did not enhance the predictive efficacy for in-hospital mortality. For mechanical ventilation, the AUC for N-GSDMD was 0.667 (95% CI, 0.532–0.802) with a sensitivity of 0.667 and a specificity of 0.825. The AUC for MPO-DNA was 0.773 (95% CI, 0.663–0.882) with a sensitivity of 0.733 and a specificity of 0.700. The combination of N-GSDMD and MPO-DNA showed a higher predictive efficacy, with an AUC of 0.755 (95% CI, 0.641–0.869) and a sensitivity of 0.630 and a specificity of 0.850.

3.4 Glycocalyx biomarkers in the sepsis - induced coagulopathy group

Biomarkers of the glycocalyx were also examined. Syndecan-1 [367.754 (300.579–416.171) vs. 431.186 (407.071–463.492), p < 0.001] was significantly higher in the SIC group compared to the non-SIC group. Similarly, MMP-9 [121.550 (104.902–138.334) vs. 133.931 (119.348–149.891), p = 0.009] levels were also higher in the SIC group (shown in Table 6, Figure 4).

Figure 4

3.5 Relationship between GSDMD-NETs axis markers and glycocalyx biomarkers

We hypothesized that the GSDMD-NETs axis interacts closely with glycan damage in the development of SIC. Pearson analysis revealed significant correlations between MPO-DNA and syndecan-1 (r = 0.856, p < 0.001), between MPO-DNA and MMP-9 (r = 0.595, p < 0.001), between N-GSDMD and syndecan-1 (r = 0.343, p = 0.004), and between N-GSDMD and MMP-9 (r = 0.509, p = 0.042)(Figure 5).

Figure 5

4 Discussion

This study provides the first human evidence specifically regarding the activation of the systemic GSDMD - NETs axis within the pathophysiology of SIC. To delineate the pathophysiological role of this axis in septic coagulopathy, we quantified plasma N-GSDMD (executioner of pyroptotic NETosis) and MPO-DNA (hallmark NET complexes), revealing marked elevations in SIC patients versus non-SIC controls: MPO-DNA [median (IQR): 461.847 (416.237–487.910) vs. 376.708 (325.89–445.34), P<0.001]; N-GSDMD [539.033 (507.33–602.98) vs. 481.302 (459.55–528.52), P<0.001]. Mechanistically, GSDMD-NETs activation emerged as an independent SIC predictor (MPO-DNA: OR 1.015, 95%CI 1.005–1.025; N-GSDMD: OR 1.018, 95%CI 1.005–1.031). Clinically, ROC analysis positioned these biomarkers as sensitive stratifiers for SIC development (AUC: 0.772 [MPO-DNA] vs. 0.786 [N-GSDMD]; combined AUC 0.859), mechanical ventilation requirement (AUC 0.718–0.742), and mortality risk (AUC 0.753–0.769). Notably, SIC patients exhibited virological predisposition (31.4% viral infections), neutrophil-dominant inflammation (elevated NLR), and hemorrhagic diathesis (48.6% bleeding events). These findings collectively establish SIC as a distinct immunothrombotic phenotype with accelerated organ dysfunction trajectories.

To our knowledge, this study represents the first prospective clinical investigation that focuses on the activation of the GSDMD - NETs axis in sepsis patients who develop SIC. With evolving understanding of sepsis pathophysiology, accumulating evidence highlights the interplay between immune dysregulation and coagulation disturbances in driving immunothrombosis, thereby contributing to SIC development. The emergence of SIC frequently portends unfavorable clinical outcomes. A study of 1,895 Japanese ICU patients demonstrated that 29% of sepsis patients met SIC diagnostic criteria (19). A large-scale analysis of 9,432 sepsis cases further confirmed SIC as an independent risk factor for 7- and 28-day mortality (adjusted OR=1.52), with distinct survival curve separation between SIC and non-SIC cohorts (20). These findings underscore the critical importance of early SIC identification and intervention in sepsis management. Neutrophils, the most rapidly recruited and abundant immune cells in sepsis, undergo cytoskeletal reorganization during sepsis progression to release neutrophil extracellular traps (NETs)—web-like structures that entrap pathogens (21). Recent clinical studies have increasingly elucidated the intricate relationship between NETs and coagulation activation (22–24), positioning NETs as a promising therapeutic target for SIC. Building upon clinical evidence demonstrating that SARS-CoV-2 virus directly activates the GSDMD pathway to trigger NET release and mediate organ damage in COVID-19 patients (25), where analysis of blood and lung tissue samples from hospitalized patients revealed GSDMD expression and NET formation associated with disease severity. Emerging preclinical evidence from murine sepsis models reveals that Gasdermin D (GSDMD) generates its N-terminal domain (N-GSDMD), which facilitates NET release through plasma membrane pore formation. Genetic ablation of GSDMD or pharmacological inhibition (e.g., LDC7559) markedly reduces NET generation and prolongs survival in septic mice, identifying the GSDMD-NETs axis as a pivotal regulatory node (5, 6).These mechanistic insights not only deepen our interest in this pathway but also prompt our hypothesis: biomarkers of GSDMD-NETs axis activation may hold significant clinical relevance in sepsis patients with SIC. In this study, for the first time in the specific context of SIC, we demonstrate that sepsis patients with SIC show significantly elevated plasma levels of GSDMD - NETs signature proteins (N - GSDMD and MPO - DNA), and these elevations independently correlate with the risk of SIC. Serum concentrations of these biomarkers effectively predict disseminated intravascular coagulation (DIC), mechanical ventilation requirement, and in-hospital mortality during sepsis. These findings provide clinical validation for the pathophysiological significance of the GSDMD-NETs axis in SIC progression.

At the cellular level, vascular endothelial cells play a pivotal role in maintaining hemostatic balance (26). The endothelial glycocalyx, composed of proteoglycans and glycosaminoglycans, preserves vascular homeostasis through electrostatic repulsion, anticoagulant molecule adsorption, and intercellular junction stabilization (27). However, this fragile structure is susceptible to degradation during sepsis. Syndecan-1, a core proteoglycan component of the glycocalyx, sheds into circulation upon glycocalyx injury (8, 9). Lipopolysaccharides (LPS) further exacerbate this damage by activating matrix metalloproteinase-9 (MMP-9) via Toll-like receptor 4 (TLR4), directly degrading glycocalyx components, exposing subendothelial collagen, and inducing tissue factor expression to establish a procoagulant microenvironment (10, 11). Prior studies have consistently linked elevated syndecan-1 and MMP-9 levels to adverse outcomes and multi-organ dysfunction in sepsis (28–30). Our findings align with this evidence, demonstrating significantly higher circulating MMP-9 and syndecan-1 levels in SIC patients compared to non-SIC counterparts, indicative of more severe glycocalyx disruption (24). Intriguingly, our data reveal a robust correlation between GSDMD-NETs axis activation and glycocalyx injury biomarkers: MPO-DNA exhibited strong associations with syndecan-1 (r = 0.856, p < 0.001) and MMP-9 (r = 0.595, p < 0.001), while N-GSDMD correlated moderately with syndecan-1 (r = 0.503, p = 0.004) and MMP-9 (r = 0.409, p = 0.042). This parallels prior evidence highlighting neutrophil-endothelial interactions as critical drivers of coagulopathy in sepsis (31). Notably, while GSDMD-NETs have been implicated in thrombosis during non-inflammatory conditions such as sickle cell anemia (32), their role in SIC pathogenesis remains underexplored. Our study provides novel clinical evidence supporting the hypothesis that GSDMD-NETs axis activation may be involved in SIC progression through glycocalyx destabilization.

Our study yielded several intriguing clinical observations. Compared to the non-SIC group, a higher proportion of SIC patients developed sepsis secondary to viral infections, suggesting that viruses may predispose to SIC more readily than bacterial pathogens. This aligns with post-COVID-19 pandemic findings, where autopsy studies of fatal COVID-19 cases revealed widespread thrombotic events and vascular endothelial injury (33), underscoring the need for heightened vigilance against SIC in viral sepsis management. Notably, while the incidence of thrombotic events did not significantly differ between SIC and non-SIC groups (51.4% vs. 45.7%, P=0.632), the SIC cohort exhibited a markedly elevated risk of hemorrhagic complications (48.6% vs. 17.1%). Based on current guidelines (34), we advocate initiating anticoagulation therapy upon SIC diagnosis. However, clinicians must remain cautious: the concurrent depletion of coagulation substrates, thrombocytopenia, and immunothrombosis in SIC patients substantially amplifies bleeding risks. Close monitoring for hemorrhagic manifestations is critical during treatment. These findings should be interpreted with caution due to our study’s limited sample size, necessitating validation through larger-scale clinical investigations to clarify the interplay between viral etiology, SIC pathophysiology, and anticoagulation-associated bleeding risks.

This study has several limitations. Firstly, the single-center design, relatively small sample size, and inability to conduct subgroup analyses based on pathogen types (e.g., bacterial, viral, fungal infections) may constrain the generalizability of findings and limit insights into pathogen-specific heterogeneity in GSDMD-NETs axis activation among sepsis patients. Future multi-center studies with larger cohorts are needed to validate these findings and explore such heterogeneity. Secondly, in this study, we mainly used the ELISA to measure the markers of the GSDMD - NETs axis (N - GSDMD, MPO - DNA) and the markers of glycocalyx damage (syndecan - 1, MMP - 9), and analyzed their correlations. The detection method was relatively single, and no other methods were used for verification. For example, zymography could be used to measure the activity of MMP - 9, and the release of NETs could be quantified by immunofluorescence after isolating neutrophils. More experimental methods are needed for verification in the future. Thirdly, although GSDMD-NETs biomarker levels were measured within 24 hours of admission, longitudinal monitoring during treatment was lacking, leaving the temporal dynamics of this pathway unexplored. Future investigations incorporating serial sampling at multiple time points may clarify the evolving relationship between GSDMD-NETs axis activation, coagulation disturbances, and organ dysfunction, thereby informing targeted therapeutic strategies.

5 Conclusions

Elevated levels of GSDMD-NETs axis biomarkers (N-GSDMD and MPO-DNA) were significantly associated with the incidence of SIC, mechanical ventilation requirement, and in-hospital mortality in sepsis patients, demonstrating a significant relationship with glycocalyx damage.

References

• 1

  Shankar-HariMPhillipsGSLevyMLSeymourCWLiuVXDeutschmanCSet al. Developing a new definition and assessing new clinical criteria for septic shock: for the third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA. (2016) 315:775–87. doi: 10.1001/jama.2016.0289

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article

• 2

  MezianiFIbaTLevyJHHelmsJ. Sepsis-induced coagulopathy: a matter of timeline. Intensive Care Med. (2024) 50:1404–5. doi: 10.1007/s00134-024-07507-3

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article

• 3

  KumarSPayalNSrivastavaVKKaushikSSaxenaJJyotiA. Neutrophil extracellular traps and organ dysfunction in sepsis. Clin Chim Acta. (2021) 523:152–62. doi: 10.1016/j.cca.2021.09.012

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article

• 4

  ZhuLDongHLiLLiuX. The mechanisms of sepsis induced coagulation dysfunction and its treatment. J Inflammation Res. (2025) 18:1479–95. doi: 10.2147/JIR.S504184

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article

• 5

  ShiJZhaoYWangKShiXWangYHuangHet al. Cleavage of GSDMD by inflammatory caspases determines pyroptotic cell death. Nature. (2015) 526:660–5. doi: 10.1038/nature15514

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article

• 6

  SollbergerGChoidasABurnGLHabenbergerPDi LucreziaRKordesSet al. Gasdermin D plays a vital role in the generation of neutrophil extracellular traps. Sci Immunol. (2018) 3. doi: 10.1126/sciimmunol.aar6689

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article

• 7

  MiddletonEAHeXDenormeFCampbellRANgDSalvatoreSPet al. Neutrophil extracellular traps contribute to immunothrombosis in COVID-19 acute respiratory distress syndrome. Blood. (2020) 136:1169–79. doi: 10.1182/blood.2020007008

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article

• 8

  ChelazziCVillaGMancinelliPDe GaudioARAdembriC. Glycocalyx and sepsis-induced alterations in vascular permeability. Crit Care. (2015) 19:26. doi: 10.1186/s13054-015-0741-z

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article

• 9

  BeckerBFChappellDBrueggerDAnneckeTJacobM. Therapeutic strategies targeting the endothelial glycocalyx: acute deficits, but great potential. Cardiovasc Res. (2010) 87:300–10. doi: 10.1093/cvr/cvq137

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article

• 10

  IbaTLevyJH. Inflammation and thrombosis: roles of neutrophils, platelets and endothelial cells and their interactions in thrombus formation during sepsis. J Thromb Haemost. (2018) 16:231–41. doi: 10.1111/jth.13911

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article

• 11

  VirziGMMattiottiMde CalMRoncoCZanellaMDe RosaS. Endotoxin in sepsis: methods for LPS detection and the use of omics techniques. Diagnostics (Basel). (2022) 13:1–17. doi: 10.3390/diagnostics13010079

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article

• 12

  SaorayaJWongsamitaLSrisawatNMusikatavornK. The effects of a limited infusion rate of fluid in the early resuscitation of sepsis on glycocalyx shedding measured by plasma syndecan-1: a randomized controlled trial. J Intensive Care. (2021) 9:1. doi: 10.1186/s40560-020-00515-7

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article

• 13

  ButlerMJRamnathRKadoyaHDespositoDRiquier-BrisonAFergusonJKet al. Aldosterone induces albuminuria via matrix metalloproteinase-dependent damage of the endothelial glycocalyx. Kidney Int. (2019) 95:94–107. doi: 10.1016/j.kint.2018.08.024

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article

• 14

  RamnathRDButlerMJNewmanGDesideriSRussellALayACet al. Blocking matrix metalloproteinase-mediated syndecan-4 shedding restores the endothelial glycocalyx and glomerular filtration barrier function in early diabetic kidney disease. Kidney Int. (2020) 97:951–65. doi: 10.1016/j.kint.2019.09.035

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article

• 15

  ZhangDQiBZhuWWHuangXWangX. Crocin alleviates lipopolysaccharide-induced acute respiratory distress syndrome by protecting against glycocalyx damage and suppressing inflammatory signaling pathways. Inflammation Res. (2020) 69:267–78. doi: 10.1007/s00011-019-01314-z

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article

• 16

  SeymourCWLiuVXIwashynaTJBrunkhorstFMReaTDScheragAet al. Assessment of clinical criteria for sepsis: for the third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA. (2016) 315:762–74. doi: 10.1001/jama.2016.0288

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article

• 17

  IbaTDi NisioMLevyJHKitamuraNThachilJ. New criteria for sepsis-induced coagulopathy (SIC) following the revised sepsis definition: a retrospective analysis of a nationwide survey. BMJ Open. (2017) 7:e17046. doi: 10.1136/bmjopen-2017-017046

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article

• 18

  EvansLRhodesAAlhazzaniWAntonelliMCoopersmithCMFrenchCet al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021. Crit Care Med. (2021) 49:e1063–143. doi: 10.1097/CCM.0000000000005337

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article

• 19

  HayakawaMOnoK. A summary of the Japan septic disseminated intravascular coagulation study. Acute Med Surg. (2018) 5:123–8. doi: 10.1002/ams2.326

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article

• 20

  LuZZhangJHongJWuJLiuYXiaoWet al. Development of a nomogram to predict 28-day mortality of patients with sepsis-induced coagulopathy: an analysis of the MIMIC-III database. Front Med (Lausanne). (2021) 8:661710. doi: 10.3389/fmed.2021.661710

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article

• 21

  DelabrancheXHelmsJMezianiF. Immunohaemostasis: a new view on haemostasis during sepsis. Ann Intensive Care. (2017) 7:117. doi: 10.1186/s13613-017-0339-5

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article

• 22

  YangSQiHKanKChenJXieHGuoXet al. Neutrophil extracellular traps promote hypercoagulability in patients with sepsis. Shock. (2017) 47:132–9. doi: 10.1097/SHK.0000000000000741

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article

• 23

  StielLMayeur-RousseCHelmsJMezianiFMauvieuxL. First visualization of circulating neutrophil extracellular traps using cell fluorescence during human septic shock-induced disseminated intravascular coagulation. Thromb Res. (2019) 183:153–8. doi: 10.1016/j.thromres.2019.09.036

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article

• 24

  MaoJZhangJChengWChenJCuiN. Effects of neutrophil extracellular traps in patients with septic coagulopathy and their interaction with autophagy. Front Immunol. (2021) 12:757041. doi: 10.3389/fimmu.2021.757041

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article

• 25

  SilvaCMSWanderleyCWSVerasFPGonçalvesAVLimaMHFToller-KawahisaJEet al. Gasdermin-D activation by SARS-CoV-2 triggers NET and mediate COVID-19 immunopathology. Crit Care. (2022) 26:206. doi: 10.1186/s13054-022-04062-5

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article

• 26

  OpalSMvan der PollT. Endothelial barrier dysfunction in septic shock. J Intern Med. (2015) 277:277–93. doi: 10.1111/joim.12331

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article

• 27

  Van TeeffelenJWBrandsJStroesESVinkH. Endothelial glycocalyx: sweet shield of blood vessels. Trends Cardiovasc Med. (2007) 17:101–5. doi: 10.1016/j.tcm.2007.02.002

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article

• 28

  PiottiANovelliDMeessenJMTAFerliccaDCoppolecchiaSMarinoAet al. Endothelial damage in septic shock patients as evidenced by circulating syndecan-1, sphingosine-1-phosphate and soluble VE-cadherin: a substudy of ALBIOS. Crit Care. (2021) 25:113. doi: 10.1186/s13054-021-03545-1

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 29

  HatanakaKItoTMadokoroYKamikokuryoCNiiyamaSYamadaSet al. Circulating syndecan-1 as a predictor of persistent thrombocytopenia and lethal outcome: A population study of patients with suspected sepsis requiring intensive care. Front Cardiovasc Med. (2021) 8:730553. doi: 10.3389/fcvm.2021.730553

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 30

  ZhangW. Critical roles of S100A12, MMP9, and PRTN3 in sepsis diagnosis: Insights from multiple microarray data analyses. Comput Biol Med. (2024) 171:108222. doi: 10.1016/j.compbiomed.2024.108222

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 31

  DenningN-LAzizMGurienSDWangP. DAMPs and NETs in sepsis. Front Immunol. (2019) 10:2536. doi: 10.3389/fimmu.2019.02536

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 32

  VatsRKaminskiTWBrzoskaTLeechJATutuncuogluEKatochOet al. Liver-to-lung microembolic NETs promote gasdermin D-dependent inflammatory lung injury in sickle cell disease. Blood. (2022) 140:1020–37. doi: 10.1182/blood.2021014552

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 33

  CarsanaLSonzogniANasrARossiRSPellegrinelliAZerbiPet al. Pulmonary post-mortem findings in a series of COVID-19 cases from northern Italy: a two-centre descriptive study. Lancet Infect Dis. (2020) 20:1135–40. doi: 10.1016/S1473-3099(20)30434-5

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 34

  IbaTLevyJHWarkentinTEThachilJvan der PollTLeviMet al. Diagnosis and management of sepsis-induced coagulopathy and disseminated intravascular coagulation. J Thromb Haemost. (2019) 17:1989–94. doi: 10.1111/jth.14578

  • Pubmed Abstract
  • CrossRef
  • Google Scholar